使CAR-T

Mei-Chi Su1,2, Agnish Dey1, Erfan Maddah1

  • 1Cell Therapy Clinical Pharmacology and Modeling, Precision and Translational Medicine, Oncology Cell Therapy and Therapeutic Area Unit, Takeda Pharmaceuticals, Cambridge, Massachusetts, USA.

概括

双向的仿真抗原受体 (CAR) T细胞疗法显示出希望,但需要了解其剂量反应. 这项研究开发了一种动力学 - 药理学模型,以优化双CAR T 细胞疗法,以获得更好的患者结果.